SE0202134D0 - Therapeutic agents - Google Patents

Therapeutic agents

Info

Publication number
SE0202134D0
SE0202134D0 SE0202134A SE0202134A SE0202134D0 SE 0202134 D0 SE0202134 D0 SE 0202134D0 SE 0202134 A SE0202134 A SE 0202134A SE 0202134 A SE0202134 A SE 0202134A SE 0202134 D0 SE0202134 D0 SE 0202134D0
Authority
SE
Sweden
Prior art keywords
sup
sub
group
optionally substituted
fluoro
Prior art date
Application number
SE0202134A
Other languages
English (en)
Swedish (sv)
Inventor
Kay Brickmann
Anna Linusson
Asim Ray
Pernilla Sandberg
Anette Svensson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0202134A priority Critical patent/SE0202134D0/xx
Publication of SE0202134D0 publication Critical patent/SE0202134D0/xx
Priority to TW092118207A priority patent/TW200412957A/zh
Priority to RU2004138079/04A priority patent/RU2004138079A/ru
Priority to BR0312312-0A priority patent/BR0312312A/pt
Priority to AU2003281194A priority patent/AU2003281194A1/en
Priority to MXPA05000336A priority patent/MXPA05000336A/es
Priority to PCT/GB2003/002884 priority patent/WO2004004726A1/en
Priority to PL03374674A priority patent/PL374674A1/xx
Priority to JP2004518963A priority patent/JP2006501186A/ja
Priority to CA002491835A priority patent/CA2491835A1/en
Priority to EP03740771A priority patent/EP1528924A1/de
Priority to US10/520,372 priority patent/US20060247439A1/en
Priority to CN038160749A priority patent/CN1665502A/zh
Priority to AR20030102464A priority patent/AR040476A1/es
Priority to IL16584104A priority patent/IL165841A0/xx
Priority to NO20045528A priority patent/NO20045528L/no
Priority to ZA200500030A priority patent/ZA200500030B/en
Priority to IS7653A priority patent/IS7653A/is
Priority to CO05007427A priority patent/CO5680403A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Quinoline Compounds (AREA)
SE0202134A 2002-07-08 2002-07-08 Therapeutic agents SE0202134D0 (sv)

Priority Applications (19)

Application Number Priority Date Filing Date Title
SE0202134A SE0202134D0 (sv) 2002-07-08 2002-07-08 Therapeutic agents
TW092118207A TW200412957A (en) 2002-07-08 2003-07-03 Therapeutic agents
CN038160749A CN1665502A (zh) 2002-07-08 2003-07-04 Mchir拮抗剂
JP2004518963A JP2006501186A (ja) 2002-07-08 2003-07-04 Ｍｃｈ１ｒアンタゴニスト
US10/520,372 US20060247439A1 (en) 2002-07-08 2003-07-04 Mchir antagonists
AU2003281194A AU2003281194A1 (en) 2002-07-08 2003-07-04 Mchir antagonists
MXPA05000336A MXPA05000336A (es) 2002-07-08 2003-07-04 Antagonistas del receptor 1 de hormona de concentracion de melanina (mchir).
PCT/GB2003/002884 WO2004004726A1 (en) 2002-07-08 2003-07-04 Mchir antagonists
PL03374674A PL374674A1 (en) 2002-07-08 2003-07-04 Mchir antagonists
RU2004138079/04A RU2004138079A (ru) 2002-07-08 2003-07-04 Антагонисты рецептора-1 меланин-концентрирующего гормона (мсн1r)
CA002491835A CA2491835A1 (en) 2002-07-08 2003-07-04 Mch1r antagonists
EP03740771A EP1528924A1 (de) 2002-07-08 2003-07-04 Mch1r antagonisten
BR0312312-0A BR0312312A (pt) 2002-07-08 2003-07-04 Composto, formulação farmacêutica, uso de um composto, processo para a preparação de compostos, e, intermediários
AR20030102464A AR040476A1 (es) 2002-07-08 2003-07-08 N-cicloalquil, aril o heteroaril n'-quinolin-2-il alquildiaminas y su uso como antagonistas de mch (hormona concentradora de melanina)
IL16584104A IL165841A0 (en) 2002-07-08 2004-12-16 Mchir antagonists
NO20045528A NO20045528L (no) 2002-07-08 2004-12-17 MHC1R-antagonister
ZA200500030A ZA200500030B (en) 2002-07-08 2005-01-03 MCH1r antagonists.
IS7653A IS7653A (is) 2002-07-08 2005-01-19 MCHIR mótlyf
CO05007427A CO5680403A2 (es) 2002-07-08 2005-01-28 Antagonistas de mchr1r

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0202134A SE0202134D0 (sv) 2002-07-08 2002-07-08 Therapeutic agents

Publications (1)

Publication Number Publication Date
SE0202134D0 true SE0202134D0 (sv) 2002-07-08

Family

ID=20288471

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0202134A SE0202134D0 (sv) 2002-07-08 2002-07-08 Therapeutic agents

Country Status (19)

Country Link
US (1) US20060247439A1 (de)
EP (1) EP1528924A1 (de)
JP (1) JP2006501186A (de)
CN (1) CN1665502A (de)
AR (1) AR040476A1 (de)
AU (1) AU2003281194A1 (de)
BR (1) BR0312312A (de)
CA (1) CA2491835A1 (de)
CO (1) CO5680403A2 (de)
IL (1) IL165841A0 (de)
IS (1) IS7653A (de)
MX (1) MXPA05000336A (de)
NO (1) NO20045528L (de)
PL (1) PL374674A1 (de)
RU (1) RU2004138079A (de)
SE (1) SE0202134D0 (de)
TW (1) TW200412957A (de)
WO (1) WO2004004726A1 (de)
ZA (1) ZA200500030B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200507112B (en) * 2003-03-31 2007-03-28 Taisho Pharmaceutical Co Ltd Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
EP1464335A3 (de) * 2003-03-31 2007-05-09 Taisho Pharmaceutical Co. Ltd. Chinolin-, Tetrahydrochinolin- und Pyrimidinderivate als MCH Antagonisten
GB0400193D0 (en) * 2004-01-07 2004-02-11 Astrazeneca Ab Therapeutic agents
WO2005066132A1 (en) * 2004-01-07 2005-07-21 Astrazeneca Ab Therapeutic agents i
EP1730122A2 (de) * 2004-03-30 2006-12-13 Taisho Pharmaceutical Co., Ltd Pyrimidinderivate und mit deren verwendung in zusammenhang stehende behandlungsverfahren
WO2006015279A1 (en) * 2004-07-28 2006-02-09 Neurogen Corporation Heterocyclic diamine compounds as ligands of the melanin concentrating hormone receptor useful for the treatment of obesity, diabetes, eating and sexual disorders
WO2006035967A1 (en) * 2004-09-30 2006-04-06 Taisho Pharmaceutical Co., Ltd. Pyridine derivatives and their use as medicaments for treating diseases related to mch receptor
JP5072602B2 (ja) * 2004-12-17 2012-11-14 イーライ リリー アンド カンパニー Ｍｃｈ受容体アンタゴニストとしてのチアゾロピリジノン誘導体
US7750034B2 (en) 2006-01-25 2010-07-06 Merck Sharp & Dohme Corp. Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
FR2902100A1 (fr) * 2006-06-13 2007-12-14 Sanofi Aventis Sa Molecules duales contenant un derive peroxydique, leur synthese et leurs applications en therapeutique
CN101516852B (zh) 2006-09-28 2011-11-16 弗·哈夫曼-拉罗切有限公司 具有5-ht结合特性的喹啉衍生物
EP2348857B1 (de) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Neue cyclische benzimidazolderivate als antidiabetika
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
SA110310332B1 (ar) 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
RU2641648C1 (ru) 2009-12-04 2018-01-19 Суновион Фармасьютикалз, Инк. Полициклические соединения и способы их применения
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
PE20130781A1 (es) 2010-07-06 2013-07-20 Astrazeneca Ab Agentes terapeuticos 976
MX348131B (es) 2011-02-25 2017-05-26 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
MX2015001500A (es) 2012-08-02 2015-04-08 Merck Sharp & Dohme Compuestos antidiabeticos triciclicos.
AU2014219020A1 (en) 2013-02-22 2015-07-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN116283877A (zh) 2016-07-29 2023-06-23 赛诺维信制药公司 化合物、组合物及其用途
KR20190065246A (ko) 2016-07-29 2019-06-11 선오비온 파마슈티컬스 인코포레이티드 화합물 및 조성물 및 이들의 용도
EP3551176A4 (de) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetische heterocyclische verbindungen
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
WO2018119395A1 (en) * 2016-12-23 2018-06-28 Aquinnah Pharmaceuticals, Inc. Compouns, compositions and methods of use
MX2019009763A (es) 2017-02-16 2019-11-21 Sunovion Pharmaceuticals Inc Metodos para tratar esquizofrenia.
SG11202000669VA (en) 2017-08-02 2020-02-27 Sunovion Pharmaceuticals Inc Isochroman compounds and uses thereof
WO2019161238A1 (en) 2018-02-16 2019-08-22 Sunovion Pharmaceuticals Inc. Salts, crystal forms, and production methods thereof
AU2020236225A1 (en) 2019-03-14 2021-09-16 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
KR20230003503A (ko) 2020-04-14 2023-01-06 선오비온 파마슈티컬스 인코포레이티드 신경학적 및 정신의학적 장애의 치료를 위한 (S)-(4,5-디히드로-7H-티에노[2,3-c]피란-7-일)-N-메틸메탄아민
US20240217951A1 (en) 2022-09-23 2024-07-04 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
US20240228469A1 (en) 2022-09-23 2024-07-11 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
US20240239767A1 (en) 2022-12-16 2024-07-18 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3020283A (en) * 1958-10-20 1962-02-06 Abbott Lab Bis-lepidines
JPH05507702A (ja) * 1990-05-30 1993-11-04 アメリカン・ホーム・プロダクツ・コーポレイション 置換アリールスルホンアミド類およびベンズアミド類
AU2764797A (en) * 1996-05-14 1997-12-05 Novo Nordisk A/S Somatostatin agonists and antagonists
EP0973513A4 (de) * 1996-10-23 2003-03-19 Zymogenetics Inc Zusammenstellungen und verfahren zur behandlung von knochenmangelerscheinungen
HUP0103093A3 (en) * 1998-04-29 2002-03-28 Smithkline Beecham Plc Quinolones used as mrs inhibitors and bactericides and process for their preparation
DE69919707T2 (de) * 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
DK1285651T3 (da) * 2000-04-28 2010-12-13 Takeda Pharmaceutical Melanin-koncentrerende hormon-antagonister
CA2433090A1 (en) * 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
JP2004524295A (ja) * 2001-01-26 2004-08-12 スミスクライン・ビーチャム・コーポレイション ウロテンシン−ｉｉ受容体アンタゴニスト

Also Published As

Publication number Publication date
ZA200500030B (en) 2005-11-11
US20060247439A1 (en) 2006-11-02
CN1665502A (zh) 2005-09-07
IL165841A0 (en) 2006-01-15
AU2003281194A1 (en) 2004-01-23
CA2491835A1 (en) 2004-01-15
IS7653A (is) 2005-01-19
AR040476A1 (es) 2005-04-06
MXPA05000336A (es) 2005-03-31
TW200412957A (en) 2004-08-01
JP2006501186A (ja) 2006-01-12
BR0312312A (pt) 2005-04-12
EP1528924A1 (de) 2005-05-11
WO2004004726A1 (en) 2004-01-15
RU2004138079A (ru) 2005-08-10
NO20045528L (no) 2005-04-04
PL374674A1 (en) 2005-10-31
CO5680403A2 (es) 2006-09-29

Similar Documents

Publication Publication Date Title
SE0202134D0 (sv) Therapeutic agents
AR046186A1 (es) Compuestos derivados de 1,3,8-triaza-espiro[4.5]decan-4-ona
HUP0303148A2 (hu) CB1 antagonista hatású 4,5-dihidro-1H-pirazol-származékok és e vegyületeket tartalmazó gyógyászati készítmények és eljárások az előállításukra
MX2007006896A (es) Fenil-metanonas bi- y triciclicas sustituidas como inhibidores del transportador 1 de glicina (glyt-1) para el tratamiento de la enfermedad de alzheimer.
RU2008111991A (ru) Органические соединения
SE0104332D0 (sv) Therapeutic agents
TW200621760A (en) 2-morpholino-4-pyrimidone compound
HRP20050708A2 (en) Piperidine-benzenesulfonamide derivatives
HUP0402107A2 (hu) N-helyettesített pirrolidinszármazékok, mint dipeptidil-peptidáz IV inhibítorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
MX2007003722A (es) Derivados de 6-(piridinil)-4-pirimidona como inhibidores de la tau proteina cinasa 1.
IS2293B (is) Arýl sambrædd asapólýsýklísk efnasambönd
HUP0301671A2 (hu) 4-Fenil-piridin-származékok, mint neurokinin-1-receptor antagonisták, eljárás az előállításukra és alkalmazásuk
NO20015686L (no) Nye forbindelser, deres anvendelse og fremstilling
EA200870358A1 (ru) 2-(циклический амино) пиримидоновые производные в качестве ингибиторов tpk1
EA200601192A1 (ru) ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ 8'-ПИРИ(МИ)ДИНИЛДИГИДРОСПИРО[ЦИКЛОАЛКИЛАМИН]ПИРИМИДО[1,2-a]ПИРИМИДИН-6-ОНА
RU2009103307A (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ
HUP0203874A2 (hu) Helyettesített 4-(fenil-N-alkil)piperazin és piperidinszármazékok és alkalmazásuk dopamin neurotranszmissziós modulátorként és ezeket tartalmazó gyógyszerkészítmények
MXPA05002420A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos.
TW200504070A (en) 8-substituted-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
MXPA05010112A (es) Derivados 8-perfluoroalquil-6, 7, 8, 9-tetrahidropirimido [1,2-a] pirimidin-4 -ona substituidos.
TW200635589A (en) Therapeutic agents
MX2009009384A (es) Malonamidas como antagonistas de orexina.
MXPA05009574A (es) Derivados de 8'-piridinil- dihidrospiro -[cicloalquil]- pirimido[1, 2a] pirimidin-6- ona y y 8'-pirimidinil- dihidrospiro -[cicloalquil]- pirimido [1, 2a]pirimidin-6 -ona substituidos y su uso contra enfermedades neurodegenerativas.
MX2011007272A (es) Piperidinas de aroilamino y heteroaroilamino sustituidas como inhibidores de glyt-1.
HUP0401883A2 (hu) Muszkarin agonisták és ezeket tartalmazó gyógyászati készítmények